Opko Health (OPK) one of the most heavily shorted companies on the NYSE. However, Billionaire investor and entrepreneur Phillip Frost, who owns 39% of the stock, has made a big bet on this small medical company. A stock analyst at Ladenburg projected as much as $3B in annual sales for its Alzheimer's blood test and told investors to expect validation of its biomarker technology by mid-2012. Opko's other leading diagnostics program is a prostate-cancer test. Opko shares are worth $1 or $2 at best unless its new diagnostic tests are successful, Barron's contends. Validation studies haven't been as positive as early claims. The shares trade at $4.18.
The flap over Apple’s corporate tax strategy might sound like a snoozer, until you consider who makes up the difference …